Avidity Biosciences
Manufacturing · California, United States · 201-500 Employees
View Company Info for Free
Overview
Headquarters
10578 Science Center Dr Ste 125, San Die...Phone Number
(858) 401-7900Website
www.aviditybiosciences.comRevenue
$36.7 MillionStock Symbol
RNAIndustry
ZI Rank: 1
Signal Type
Dec
Jan
Feb
Mar
Apr
May
ZI Rank
5
6
1
2
1
1
About Avidity Biosciences
Avidity Biosciences, Inc.'s mission is to profoundly improve people's lives by delivering a new class of RNA therapeutics - Antibody Oligonucleotide Conjugates (AOCs). Avidity is broadening the reach of AOCs with its advancing and expanding pipeline including programs in cardiology and immunology through internal discovery efforts and key partnerships.Explore more
Avidity Biosciences Org Chart
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is Avidity Biosciences your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Website visits: Recent activity has been detected on your website
Avidity Biosciences, which may be a good buyer, showed buying intent in Masked Content Topic
Congratulate Masked Content for being promoted to Masked Content at Avidity Biosciences
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Click to see if Avidity Biosciences had a recent Job posting/layoffs
Check out if Avidity Biosciences is spiking on competitors!
Product Launch: Get notified when Avidity Biosciences launches new products
Check if Avidity Biosciences has recently received funding, and reach out quickly before it becomes old news!
Funding: Get notified immidiatlly once Avidity Biosciences has new funding data
Earning: See what the market has to say on Avidity Biosciences recently announced quarterly report
Recommended Actions
Introduce yourself to Masked Content, who has shown a strong intent to purchase lately
Find 3 more new buyers
Compare Similar Companies to Avidity Biosciences
Compare insights from companies similar to Avidity Biosciences, focusing on performance, financial data, growth rates, and unique benchmarks to identify key industry trends and opportunities.
Revenue
Number of Employees
Type
Funding
Founded In
Company Profile Activity
Activity Insights
Avidity Biosciences is experiencing very low activity levels compared to other companies in the Manufacturing sector.
What does this means?
Avidity Biosciences is drawing exceptional interest within the Manufacturing industry, suggesting notable developments or strong market momentum, learn more about Avidity Biosciences.
Avidity Biosciences financials insights
Gather financial insights about Avidity Biosciences, including details on funding rounds, investors, total funding, and acquisitions, to gain a comprehensive understanding of their financial strategy.
2014
Series A
$9.1M
Debt
$6M
2016
Series B
$16M
2019
Series C
$100M
2020
Stock Offering
$259M
2021
Share Placement
$144M
2024
Stock Offering
$461M
2025
Stock/Share Issuance
$600M
Avidity Biosciences Tech Stack
A closer look at the technologies used by Avidity Biosciences
See more technologies
Most Recent Scoops
Project
Laboratory Operations, Medical Research, Clinical Operations
Partnership
Project
Laboratory Operations, Medical Research, Clinical Operations
Open Position
Left Company
Executive Move
Alexander Titus, Vice President, Head of AI & Data Science, has recently left the organization and now serves as Chief Executive Officer, Vigilance for Alloy Therapeutics, Inc..
Executive Moves, Left Company
Project
Laboratory Operations, Medical Research, Clinical Operations
Avidity Biosciences News & Media
Novartis successfully completes acquisition of Avidity Biosciences, strengthening late-stage neuroscience pipeline and advancing xRNA strategy
Basel, February 27, 2026 -- Novartis AG (NYSE: NVS) today announced that it has successfully completed its acquisition of Avidity Biosciences, Inc. (“Avidity”). With the completion of the acquisition, Avidity is now an indirect, wholly owned subsidiary of Novartis.Avidity Biosciences Announces Multiple Upcoming Presentations at 2026 Muscular Dystrophy Association (MDA) Clinical & Scientific Conference
SAN DIEGO, Feb. 26, 2026 /PRNewswire/ -- Avidity Biosciences, Inc. ("Avidity") (Nasdaq: RNA), a biopharmaceutical company committed to delivering a new class of RNA therapeutics called Antibody Oligonucleotide Conjugates (AOCs™) to profoundly improve people's lives, today announced that...Avidity Biosciences Delays Shareholder Meeting to Facilitate Novartis Merger and Spin-Off
Avidity Biosciences postpones its special stockholder meeting to February 26, 2026, to facilitate the spin-off of Atrium Therapeutics and the subsequent merger with Novartis, expected to close on February 27, 2026.Avidity Biosciences to reconvene special meeting Feb. 26 | RNA Stock News
Distribution of Atrium Therapeutics stock is now expected Feb. 26, with Avidity’s Novartis merger slated for Feb. 27, after a reconvened vote on Feb. 26.
Read more news
Top Manufacturing Companies
Top companies in Canada by revenue
Top companies in Australia by revenue
Top companies in New Zealand by revenue
Frequently Asked Questions Regarding Avidity Biosciences
Sign Up For FreeTo access detailed company insights
Avidity Biosciences, Inc.'s mission is to profoundly improve people's lives by delivering a new class of RNA therapeutics - Antibody Oligonucleotide Conjugates (AOCs). Avidity is broadening the reach of AOCs with its advancing and expanding pipeline including programs in cardiology and immunology through internal discovery efforts and key partnersh... Read More
